Meta-analysis · people
Thymosin Alpha-1 vs interferon in hepatitis B: better at follow-up
Checked against the paper Meta-analysisPublished by PepVault
The takeaway
In chronic hepatitis B, thymosin alpha-1 did no better than interferon alpha by the end of treatment but outperformed it 6 months later, mainly in HBeAg-negative patients.
- Kind
- Meta-analysis
- Studied in
- People
- Number studied
- 199
- Published
- 2008
- Journal
- Antiviral Res
What they tested
The team asked whether thymosin alpha-1 works better or worse than interferon alpha for treating chronic hepatitis B.
How the study was done
A meta-analysis, which pools results from several studies, of randomized controlled trials with 199 people with chronic hepatitis B who got either thymosin alpha-1 or interferon alpha. Results were checked at the end of 6 months of treatment and again 6 months after treatment stopped.

What they found
Results are given as odds ratios (OR), where a number above 1 favors thymosin alpha-1 and below 1 favors interferon alpha. At the end of 6 months of treatment, the ORs for thymosin alpha-1 were 0.62 (95% CI 0.35, 1.10) for viral response and 0.60 (0.34, 1.05) for liver enzyme response, so neither showed a clear difference, while complete response, meaning both at once, was 0.54 (0.30, 0.97), favoring interferon. Six months after treatment ended, the ORs flipped in favor of thymosin alpha-1: 3.71 (2.05, 6.71) for viral response, 3.12 (1.74, 5.62) for liver enzyme response and 2.69 (1.47, 4.91) for complete response. The authors say responses to thymosin alpha-1 seemed to build up gradually after therapy ended.
What it doesn’t show
It pools only a handful of small trials, and most of them studied HBeAg-negative patients (people whose blood lacks the hepatitis B e antigen marker), so the results mainly apply to that group. Follow-up lasted only 6 months after treatment.
The paper
Yang et al. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. Antiviral Res. 2008.
The compound
More studies on Thymosin Alpha-1
- Thymosin alpha-1 lowered infections after colorectal cancer surgeryRandomized trial · people · 2024
- Thymosin Alpha-1 combo: 30.0% pCR before gastric cancer surgeryClinical trial · people · 2026
- Every study on Thymosin Alpha-1
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.